Pembrolizumab Combined With Radiotherapy for Metastatic Sarcoma
Status:
Not yet recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
This is a single-arm clinical trial determining the feasibility of combination treatments,
pembrolizumab and stereotactic ablative radiotherapy (SBRT) in subjects with soft-tissue
sarcoma. These are subjects who have metastatic disease initially, or recurrent or
progressive disease that is not eligible for curative surgery.